查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1927404

慢性骨髓性白血病(CML) 治療市場按治療方法、分期、治療環境和患者年齡層分類 - 全球預測 2026-2032 年

Treating Chronic Myeloid Leukemia by Phase Market by Treatment Type, Phase, Treatment Setting, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

慢性骨髓性白血病(CML) 治療市場按階段分類，2025 年價值 49.2 億美元，預計 2026 年將成長至 52.6 億美元，到 2032 年將達到 80.8 億美元，複合年成長率為 7.33%。

關鍵市場統計數據
基準年 2025 49.2億美元
預計年份：2026年 52.6億美元
預測年份 2032 80.8億美元
複合年成長率 (%) 7.33%

臨床路徑的策略性引入、治療方法的演變以及相關人員的需求，共同塑造了慢性骨髓性白血病的階段特異性治療。

慢性骨髓性白血病) 的臨床病程獨特，分為三個不同的階段—慢性期、加速期和急變期—每個階段都需要量身定做的治療方案。過去二十年來，治療的基礎已從特異性細胞毒性療法和異體造血幹細胞移植轉向分子標靶抑制 BCR-ABL 激酶的藥物。這項轉變重新定義了治療目標，從單純延長存活期轉變為實現深度分子緩解、提高生活品質，並在部分患者中實現無治療緩解。

分子科學的進步、監管的演變以及醫療服務模式的變化如何重新定義慢性骨髓性白血病治療的臨床實踐和商業策略

慢性骨髓性白血病）的治療格局正經歷著變革性的轉變，這主要得益於分子科學的進步、監管創新以及醫療服務模式的演變。透過一代又一代的蛋白酪氨酸激酶抑制劑精準標靶治療BCR-ABL融合蛋白，為迭代式藥物研發樹立了先例，並整體骨髓惡性腫瘤的治療策略。同時，分子監測技術的改進和標準化的療效評估標準，使得臨床醫生能夠更早地做出個別化的治療決策，並考慮對部分患者停止治療。

評估新的貿易措施和進口成本如何重塑白血病治療的供應鏈、臨床運作和病患就醫途徑

美國2025年實施的新關稅正在對藥品供應鏈和商業營運產生連鎖反應，影響慢性骨髓性白血病治療藥物的可近性、成本結構以及策略採購決策。由於活性藥物原料藥、製劑和專用生產設備在生產過程中通常需要跨越多個國界，因此增加進口成本的關稅將推高藥品和原料的到岸成本，促使製造商重新調整生產基地。為此，一些企業正在加快生產在地化計劃，或將供應商多元化，轉向受貿易措施影響較小的地區。

關鍵細分分析揭示了治療層級、疾病階段、治療環境和年齡層如何相互作用，從而決定治療路徑和結果。

細分市場層面的趨勢分析揭示了治療方案、疾病分期、醫療環境和患者年齡如何影響慢性骨髓性白血病的臨床決策和服務設計。以治療方法進行的分析突顯了蛋白酪氨酸激酶抑制劑 (TKI) 相對於化療和造血幹細胞移植的重要性，其中第一代藥物用於控制疾病，而後續幾代藥物則用於解決抗藥性和耐受性問題。在蛋白酪氨酸激酶抑制劑家族中，第一代藥物對於初始疾病控制仍然至關重要，而第二代藥物，例如Bosutinib、Dasatinib和尼洛替尼，則常用於治療耐受性和抗藥性，並在特定患者中獲得更深層的分子學緩解。第三代藥物為具有複雜突變譜或領先治療後疾病進展的患者提供了標靶治療選擇。

醫療基礎設施、法規結構和採購慣例的區域差異如何影響全球治療方法的普及和患者獲取途徑。

區域背景對慢性骨髓性白血病新療法的可近性、治療模式和應用有著深遠的影響。在美洲，先進的門診基礎設施和強大的專科藥房網路支援口服標靶治療的廣泛應用，但不同支付方類型以及都市區地區之間仍然存在可及性差異。歐洲市場以及中東和非洲地區的情況也存在顯著差異。雖然一些歐洲醫療系統已整合了完善的分子監測和國家治療通訊協定，以促進符合指南的治療，但中東和非洲部分地區的基礎設施和資源限制了他們獲得新一代藥物和先進監測能力。在亞太地區，雖然存在高容量治療中心和快速發展的本地生產能力，但監管路徑和報銷環境差異很大，導致新藥和新興治療模式的推廣應用曲線各不相同。

策略性企業行動、合作模式和營運重點，旨在推動白血病治療領域的創新、供應鏈韌性和患者支援。

領先的藥物研發和服務供應商的企業策略將影響慢性骨髓性白血病治療創新和可及性的方向。製藥創新者持續投資於下一代激酶抑制劑，旨在提高對抗藥性克隆的療效，同時降低脫靶毒性並提高患者依從性。藥物研發公司、診斷公司和學術機構之間的合作日益普遍，從而能夠採用整合的突變來指導治療方案和簡化臨床開發流程。受託研究機構(CRO) 和專業臨床網路在執行特定階段的臨床試驗中發揮關鍵作用，尤其是在難以招募的加速期和急變期患者中。

為製造商、醫療服務提供者和支付方提供切實可行的建議，以改善治療效果、保障供應，並使循證醫學的產生與基於價值的醫療保健預期相一致。

產業領導者可以採取一系列切實可行的措施來改善慢性骨髓性白血病治療的臨床療效，確保供應連續性，並加速實現價值交付。首先，投資於整合分子檢測、數位化互動和協調個案管理的綜合監測和依從性項目，以支持治療效果的持續發揮，並在臨床合理的情況下考慮停止治療。其次，優先考慮供應鏈多元化和區域製造夥伴關係，以降低單一來源風險和關稅造成的成本波動，同時維持品質和合規性。

調查方法結合了臨床證據、監管審查、專家訪談和供應鏈情境分析，以綜合提煉出可操作的循序漸進的見解。

本研究採用多學科調查方法進行綜合分析，整合了同儕審查的臨床文獻、監管指導文件、公共衛生數據、專家訪談和最佳實踐，從而全面了解治療模式及其策略意義。研究重點關注影響疾病各階段標準治療決策的隨機對照試驗、長期觀察性研究和指南更新，並對臨床證據進行了審查。此外，研究還分析了監管和政策文件，以提取影響商業性和市場准入規劃的核准途徑、適應症擴展和報銷標準的趨勢。

整合了相關人員必須整合的臨床、營運和政策要求，以改善治療效果並維持疾病各階段的醫療服務可近性。

總之，慢性骨髓性白血病治療已發展成為一個精細化的領域，治療方法的選擇、監測強度和護理環境必須與疾病分期、患者特徵和當地基礎設施緊密結合。分子標靶治療和監測技術的進步改變了人們對深度和持久療效的預期，而商業性和政策趨勢也越來越要求可衡量的價值和可靠的真實世界證據。貿易和供應鏈趨勢，包括關稅波動，進一步加劇了營運環境的複雜性，並凸顯了韌性和策略採購規劃的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8.慢性骨髓性白血病(CML) 治療市場按分期和治療方法分類

  • 化療
  • 幹細胞移植
  • 蛋白酪氨酸激酶抑制劑
    • 第一代酪胺酸激酶抑制劑
    • 第二代TKI
      • Bosutinib
      • Dasatinib
      • 尼洛替尼
    • 第三代蛋白酪氨酸激酶抑制劑

9.慢性骨髓性白血病(CML) 治療市場（依階段分類）

  • 加速期
  • 爆炸危機
  • 慢性期

第10章慢性骨髓性白血病(CML) 治療市場依分期及治療環境分類

  • 住院病人
  • 醫院門診部
  • 專科診所

第11章慢性骨髓性白血病(CML) 治療市場按分期和患者年齡層分類

  • 成人
  • 老年人
  • 兒童

12.慢性骨髓性白血病(CML) 治療市場按階段分類：按地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章慢性骨髓性白血病(CML) 治療市場按階段分類：按組別

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14.慢性骨髓性白血病(CML) 治療市場按階段分類：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國慢性骨髓性白血病（CML）治療市場依階段分類：

第16章：中國慢性骨髓性白血病（CML）治療市場分期分析：

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation by Bristol Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Intas Pharmaceuticals Limited
  • Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
Product Code: MRR-4F7A6D4FF3A1

The Treating Chronic Myeloid Leukemia by Phase Market was valued at USD 4.92 billion in 2025 and is projected to grow to USD 5.26 billion in 2026, with a CAGR of 7.33%, reaching USD 8.08 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.92 billion
Estimated Year [2026] USD 5.26 billion
Forecast Year [2032] USD 8.08 billion
CAGR (%) 7.33%

A strategic introduction to the clinical pathways, therapeutic evolution, and stakeholder imperatives shaping phase-specific treatment of chronic myeloid leukemia

Chronic myeloid leukemia presents a distinctive clinical pathway characterized by discrete phases-chronic phase, accelerated phase, and blast crisis-each demanding a calibrated therapeutic approach. Over the past two decades, the therapeutic backbone has shifted from non-specific cytotoxic therapies and allogeneic hematopoietic stem cell transplantation toward targeted small molecules that inhibit the BCR-ABL kinase. This evolution reshaped treatment goals from merely extending survival to achieving deep molecular responses, improving quality of life, and enabling treatment-free remission in selected patients.

Clinicians and health system leaders must now navigate a more complex landscape where therapeutic selection depends on prior treatment history, mutational profile, comorbidity burden, and patient preferences. Meanwhile, regulatory frameworks and payer expectations increasingly emphasize real-world evidence and value-based outcomes, prompting manufacturers and providers to align around measurable clinical endpoints. As a result, multidisciplinary decision making-integrating hematology, transplant services, pharmacoeconomics, and patient support programs-has become essential to optimize individual patient journeys and broader service delivery.

Transitioning from historical practice to contemporary standards requires a granular understanding of the drivers of treatment choice across disease phases, the operational implications for treatment settings, and the strategic levers available to stakeholders seeking to improve outcomes while containing costs. This introduction frames the deeper analyses that follow, providing context for the clinical, commercial, and policy trends shaping care for people living with chronic myeloid leukemia.

How molecular advances, regulatory evolution, and care delivery transformation are redefining clinical practice and commercial strategies across chronic myeloid leukemia care

The therapeutic landscape for chronic myeloid leukemia is experiencing transformative shifts driven by advances in molecular science, regulatory innovations, and evolving care delivery models. Precision targeting of the BCR-ABL fusion protein through successive generations of tyrosine kinase inhibitors set a precedent for iterative drug development that now informs strategies across hematologic malignancies. Concurrently, improvements in molecular monitoring techniques and standardized response criteria have enabled clinicians to make earlier, individualized treatment decisions and to consider treatment discontinuation in carefully selected patients.

From a commercial perspective, competition among oral targeted agents has reoriented market dynamics toward differentiated safety profiles, dosing convenience, and long-term tolerability. This has triggered a downstream focus on adherence programs, digital therapeutics, and patient support services that bolster sustained molecular response. At the same time, regulatory agencies are increasingly open to adaptive approval pathways and label expansions based on surrogate markers, encouraging sponsors to generate robust translational and real-world evidence to support broader indications.

Importantly, care delivery is also shifting. Specialty clinics and outpatient infusion centers are expanding their role, enabling more decentralized management of chronic phase disease and reducing reliance on inpatient resources. These shifts create both opportunities and responsibilities for payers, providers, and industry actors to harmonize access strategies, optimize resource allocation, and ensure that innovation translates into measurable improvements in survival and quality of life across diverse patient populations.

Assessment of how new trade measures and import costs are reshaping supply chains, clinical operations, and patient access pathways for leukemia therapies

The imposition of new tariff measures by the United States in two thousand twenty-five has rippled through pharmaceutical supply chains and commercial operations in ways that affect access, cost structures, and strategic sourcing decisions for chronic myeloid leukemia therapies. Active pharmaceutical ingredients, finished dose formulations, and specialized manufacturing equipment often cross multiple borders during production; tariffs that increase import costs can therefore raise the landed cost of drugs and raw materials, prompting manufacturers to reassess production footprints. In response, some sponsors are accelerating plans to localize manufacturing or to diversify suppliers across jurisdictions less affected by trade measures.

Clinical programs and trial operations also feel the impact. Tariffs that increase the cost of investigational products or required devices can influence trial budgeting and site selection, and may complicate multinational supply logistics for phase-specific studies. Moreover, payer negotiations in the United States and in markets closely linked to its trade policy become more complex when baseline cost assumptions shift, which in turn affects formulary placement and patient access programs. Health systems and specialty clinics that manage long-term oral targeted therapies may face higher procurement expenditures, compelling pharmacy and procurement teams to renegotiate contracts and seek alternative sourcing strategies.

Policymakers, regulators, and industry actors are pursuing mitigation tactics. These include expanding bilateral manufacturing agreements, investing in regional API hubs, and leveraging tariff exemption processes where available. In parallel, manufacturers are enhancing transparency around unit costs and total cost of care to strengthen value arguments during reimbursement discussions. Clinicians and health system leaders should anticipate and plan for evolving supply chain contingencies, ensuring that contingency buffers, alternative sourcing pathways, and stakeholder communication plans are in place to preserve continuity of care through each disease phase.

Critical segmentation insights illustrating how therapeutic class, disease phase, treatment setting, and age cohorts interact to determine care pathways and outcomes

Segment-level dynamics reveal how treatment choice, disease phase, care setting, and patient age together shape clinical decision making and service design across chronic myeloid leukemia. Analysis by treatment type underscores the centrality of tyrosine kinase inhibitors relative to chemotherapy and hematopoietic stem cell transplantation, with first generation agents establishing disease control and later generations addressing resistance and tolerability. Within the tyrosine kinase inhibitor family, first generation agents remain important for initial disease control, while second generation agents such as bosutinib, dasatinib, and nilotinib are frequently utilized to manage intolerance or resistance and to achieve deeper molecular responses in selected patients. Third generation agents provide targeted options for complex mutational profiles and for patients who have progressed after earlier lines of therapy.

When viewed by disease phase, chronic phase management emphasizes long-term oral therapy and monitoring to sustain deep molecular responses and consider treatment-free remission strategies, whereas accelerated phase and blast crisis require more aggressive, often combination-based approaches and rapid escalation to transplant where appropriate. Treatment setting further modulates pathways: hospital inpatient units manage acute complications and intensive therapies; hospital outpatient clinics deliver infusions, monitoring, and complex procedural care; and specialty clinics provide longitudinal management for oral targeted therapies alongside adherence and monitoring programs. Patient age groups introduce additional complexity, as pediatric patients require dosing and psychosocial adaptations, geriatric patients present comorbidity and frailty considerations that influence tolerability, and adults represent the largest heterogeneous cohort with varying comorbidity profiles and life-stage priorities.

Together, these segmentation lenses highlight the need for integrated care pathways that align therapeutic choice to disease biology, treatment setting, and patient-specific factors, supporting optimized outcomes across phases of disease progression.

How diverse regional healthcare infrastructures, regulatory frameworks, and procurement practices shape therapy adoption and patient access globally

Regional dynamics exert a profound influence on access, care delivery models, and the adoption of novel therapies for chronic myeloid leukemia. In the Americas, systems with advanced outpatient infrastructures and strong specialty pharmacy networks support broad adoption of oral targeted therapies, yet disparities in access persist across payer types and rural versus urban settings. European markets, the Middle East, and Africa display marked heterogeneity: several European health systems integrate robust molecular monitoring and national treatment protocols that facilitate guideline-concordant care, while parts of the Middle East and Africa face infrastructure and resource constraints that limit access to later-generation agents and advanced monitoring capabilities. The Asia-Pacific region combines high-volume treatment centers and rapidly evolving local manufacturing capacity with significant variability in regulatory pathways and reimbursement environments, contributing to differentiated adoption curves for newer agents and care models.

These geographic distinctions affect everything from the pacing of clinical adoption to supply chain design. Market entrants and established manufacturers must therefore tailor strategies to regional payer expectations, local diagnostic capacity, and distribution channels. Clinics and hospital systems should align molecular monitoring protocols and telehealth-enabled follow-up approaches to regional patient needs, considering the variable availability of hematopoietic stem cell transplantation services and the differing prevalence of comorbid conditions that influence treatment tolerability. Cross-regional collaborations and knowledge sharing can accelerate best practice diffusion, but successful translation requires attention to local regulatory and operational realities.

Strategic corporate behaviors, collaborative models, and operational priorities driving innovation, supply resilience, and patient support in leukemia care

Corporate strategies among leading developers and service providers influence the trajectory of therapeutic innovation and access in chronic myeloid leukemia. Pharmaceutical innovators continue to invest in next-generation kinase inhibitors aiming to improve potency against resistant clones while reducing off-target toxicity and fostering adherence. Partnerships between drug developers, diagnostics firms, and academic centers are increasingly common, enabling integrated approaches to mutation-driven therapy selection and streamlined clinical development. Contract research organizations and specialized clinical networks play a pivotal role in running phase-specific studies, particularly those targeting accelerated phase and blast crisis populations where enrollment is more challenging.

In parallel, manufacturers and health systems are developing comprehensive patient support ecosystems encompassing molecular monitoring, adherence support, and financial navigation to maximize real-world effectiveness of oral targeted therapies. Supply chain resilience has become a strategic priority, prompting investments in geographic diversification of manufacturing and in digital supply chain visibility tools. Additionally, smaller biotech firms and academic spinouts continue to explore complementary modalities, including immunotherapeutic approaches and combination regimens that may alter future standard-of-care algorithms. Collectively, these corporate actions emphasize collaboration across the value chain to address unmet needs, reduce time to diagnosis and appropriate therapy selection, and improve longitudinal outcomes across disease phases.

Actionable recommendations for manufacturers, providers, and payers to enhance outcomes, secure supply, and align evidence generation with value-based care expectations

Industry leaders can take a series of pragmatic actions to strengthen clinical outcomes, secure supply continuity, and accelerate value delivery across chronic myeloid leukemia care. First, invest in integrated monitoring and adherence programs that combine molecular testing, digital engagement, and coordinated case management to support durable responses and enable appropriate consideration of treatment discontinuation where clinically justified. Second, prioritize supply chain diversification and regional manufacturing partnerships that reduce exposure to single-source risks and tariff-driven cost volatility while maintaining quality and regulatory compliance.

Third, align evidence generation with payer needs by embedding pragmatic real-world data collection into post-authorization safety studies and registries, thereby demonstrating value across diverse patient populations and care settings. Fourth, cultivate collaborative research partnerships with academic centers and specialty clinics to accelerate enrollment in phase-specific trials for accelerated phase and blast crisis patients, where unmet need remains highest. Fifth, tailor commercial and access strategies to regional realities, acknowledging differences in diagnostic infrastructure, reimbursement models, and patient support requirements. Finally, engage proactively with policymakers and payers to design value-based contracting models that reflect long-term outcomes and total cost of care, ensuring that innovative therapies deliver measurable benefit while remaining sustainable for healthcare systems.

Methodology that integrates clinical evidence, regulatory review, expert interviews, and supply chain scenario analysis to synthesize actionable, phase-specific insights

This research synthesis relies on a multidisciplinary methodology that integrates peer-reviewed clinical literature, regulatory guidance documents, public health data, expert interviews, and operational best practices to produce a comprehensive view of treatment patterns and strategic implications. Clinical evidence was reviewed with an emphasis on randomized controlled trials, long-term observational studies, and guideline updates that inform standard-of-care decisions across disease phases. Regulatory and policy materials were analyzed to extract trends in approval pathways, label expansions, and reimbursement criteria that alter commercial and access planning.

To contextualize commercial and operational factors, the methodology incorporated structured interviews with hematologists, transplant specialists, specialty pharmacists, and health system procurement leaders, supplementing literature findings with real-world practice insight. Supply chain and tariff impacts were assessed through scenario analysis encompassing cross-border manufacturing flows, procurement contracts, and logistics considerations. Finally, triangulation across data streams ensured that recommendations and insights reflect both empirical evidence and frontline operational experience, producing pragmatic guidance for stakeholders seeking to optimize phase-specific care delivery and strategic planning.

Synthesis of clinical, operational, and policy imperatives that stakeholders must integrate to advance outcomes and sustain access across all phases of disease

In conclusion, the treatment of chronic myeloid leukemia has evolved into a nuanced discipline where therapeutic selection, monitoring intensity, and care setting must be tightly aligned with disease phase, patient characteristics, and regional infrastructure. Advances in molecular targeting and monitoring have transformed expectations around deep and durable responses, while commercial and policy trends increasingly demand measurable value and robust real-world evidence. Trade and supply chain dynamics, including tariff shifts, further complicate the operational landscape and underscore the importance of resilience and strategic sourcing.

Moving forward, stakeholders who succeed will be those that integrate clinical excellence with agile operational strategies: investing in molecular diagnostics and adherence infrastructure, diversifying manufacturing and supply chains, and partnering across the ecosystem to generate the evidence payers require. By adopting these approaches, clinicians, manufacturers, and health systems can improve outcomes across chronic, accelerated, and blast phases of disease, while ensuring that innovation translates into accessible and sustainable care delivery.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Type

  • 8.1. Chemotherapy
  • 8.2. Stem Cell Transplantation
  • 8.3. Tyrosine Kinase Inhibitor
    • 8.3.1. First Generation TKI
    • 8.3.2. Second Generation TKI
      • 8.3.2.1. Bosutinib
      • 8.3.2.2. Dasatinib
      • 8.3.2.3. Nilotinib
    • 8.3.3. Third Generation TKI

9. Treating Chronic Myeloid Leukemia by Phase Market, by Phase

  • 9.1. Accelerated Phase
  • 9.2. Blast Crisis
  • 9.3. Chronic Phase

10. Treating Chronic Myeloid Leukemia by Phase Market, by Treatment Setting

  • 10.1. Hospital Inpatient
  • 10.2. Hospital Outpatient
  • 10.3. Specialty Clinic

11. Treating Chronic Myeloid Leukemia by Phase Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Treating Chronic Myeloid Leukemia by Phase Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Treating Chronic Myeloid Leukemia by Phase Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Treating Chronic Myeloid Leukemia by Phase Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Treating Chronic Myeloid Leukemia by Phase Market

16. China Treating Chronic Myeloid Leukemia by Phase Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Biogen Inc.
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Celgene Corporation by Bristol Myers Squibb Company
  • 17.10. Cipla Limited
  • 17.11. Dr. Reddy's Laboratories Limited
  • 17.12. Eisai Co., Ltd.
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline PLC
  • 17.16. Incyte Corporation
  • 17.17. Intas Pharmaceuticals Limited
  • 17.18. Janssen Global Services, LLC by Johnson & Johnson Services, Inc.
  • 17.19. Merck KGaA
  • 17.20. Novartis AG
  • 17.21. Pfizer Inc.
  • 17.22. Sun Pharmaceutical Industries Limited
  • 17.23. Takeda Pharmaceutical Company Limited
  • 17.24. Teva Pharmaceutical Industries Limited
  • 17.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY FIRST GENERATION TKI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BOSUTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY DASATINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY NILOTINIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY THIRD GENERATION TKI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ACCELERATED PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY BLAST CRISIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY CHRONIC PHASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY HOSPITAL OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 130. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 131. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. GCC TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 151. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 152. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 154. G7 TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 158. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 159. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 161. NATO TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TYROSINE KINASE INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY SECOND GENERATION TKI, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA TREATING CHRONIC MYELOID LEUKEMIA BY PHASE MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)